enGene (ENGN) Stock Price, News & Analysis

Company Overview

enGene Inc. is a clinical-stage biotechnology company focused on the development of gene-based therapies for cancer and ocular diseases. Founded in 2000 and headquartered in Cambridge, Massachusetts, with research facilities in Israel, enGene leverages proprietary drug‐delivery platforms to address high‐unmet‐need areas in oncology and ophthalmology. The company’s technology is designed to enhance the precision and durability of therapeutic agents by controlling the release and localization of nucleic acids in target tissues.

Central to enGene’s pipeline is the LOcal Drug EluteR (LODER®) platform, a biodegradable implant that provides sustained, site‐specific release of small interfering RNA (siRNA) within solid tumors. The lead oncology candidate, which targets mutant KRAS in pancreatic cancer, is advancing through clinical evaluation following promising safety and tolerability data. In parallel, enGene is developing a second LODER‐based therapy for head and neck cancer, as well as an ocular gene therapy program aimed at neovascular retinal disorders.

Beyond its implantable delivery system, enGene is advancing a suite of nanoparticle formulations designed to protect and transport messenger RNA (mRNA) and plasmid DNA to cells of interest. These formulations are being explored in preclinical studies for indications such as glioblastoma and age‐related macular degeneration. The company collaborates with leading academic institutions and contract research organizations across North America and Europe to accelerate translation of its proprietary platforms from bench to bedside.

Under the leadership of CEO Dan Rosenblum and a management team seasoned in pharmaceutical R&D, enGene is committed to expanding its global footprint and forging strategic partnerships. With operations spanning the U.S., Europe and Israel, the company aims to advance its novel therapeutics through clinical milestones and regulatory pathways, ultimately delivering targeted, durable treatments for patients with few options.

Key Stats

• Today's Range: $3.63 to $3.90
• 50-Day Range: $2.88 to $4.29
• 52-Week Range: $2.65 to $11.00
• Volume: 27,031 shs
• Average Volume: 122,994 shs
• Market Capitalization: $195.97 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $23.29
• Consensus Rating: Buy

enGene Stock Analysis - MarketRank™

enGene scored higher than 59% of companies evaluated by MarketBeat, and ranked 381st out of 918 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

enGene has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

enGene has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for enGene are expected to decrease in the coming year, from ($1.56) to ($1.84) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of enGene is -2.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of enGene is -2.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

enGene has a P/B Ratio of 0.72. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.26% of the float of enGene has been sold short.

Short Interest Ratio / Days to Cover

enGene has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in enGene has recently increased by 11.50%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

enGene does not currently pay a dividend.

Dividend Growth

enGene does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.26% of the float of enGene has been sold short.

Short Interest Ratio / Days to Cover

enGene has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in enGene has recently increased by 11.50%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: -0.09

News Sentiment

enGene has a news sentiment score of -0.09. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 24 news articles for enGene this week, compared to 13 articles on an average week.

Search Interest

1 people have searched for ENGN on MarketBeat in the last 30 days.

MarketBeat Follows

9 people have added enGene to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, enGene insiders have not sold or bought any company stock.

Percentage Held by Insiders

10.40% of the stock of enGene is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

64.16% of the stock of enGene is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ENGN Stock Analysis - Frequently Asked Questions

How have ENGN shares performed this year?

enGene's stock was trading at $6.65 at the beginning of 2025. Since then, ENGN stock has decreased by 42.3% and is now trading at $3.8350.

How were enGene's earnings last quarter?

enGene Holdings Inc. (NASDAQ:ENGN) released its quarterly earnings data on Tuesday, June, 10th. The company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.48) by $0.03.

How do I buy shares of enGene?

Shares of ENGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of enGene own?

Based on aggregate information from My MarketBeat watchlists, some other companies that enGene investors own include PayPal (PYPL), United Microelectronics (UMC), XPeng (XPEV), Adverum Biotechnologies (ADVM), AngioDynamics (ANGO), APi Group (APG) and Avino Silver & Gold Mines (ASM).

Company Calendar

• Last Earnings: 6/10/2025
• Today: 7/20/2025
• Next Earnings (Estimated): 9/10/2025
• Fiscal Year End: 10/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ENGN
• Previous Symbol: NASDAQ:ENGN
• CIK: 1980845
• Web: www.engene.com
• Phone: 302-273-0765
• Fax: N/A
• Employees: 31
• Year Founded: N/A

Price Target and Rating

• Average Price Target for enGene: $23.29
• High Price Target: $34.00
• Low Price Target: $7.00
• Potential Upside/Downside: +514.4%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.65)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$55.14 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -32.60%
• Return on Assets: -28.26%

Debt

• Debt-to-Equity Ratio: 0.09
• Current Ratio: 12.66
• Quick Ratio: 12.66

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $5.35 per share
• Price / Book: 0.71

Miscellaneous

• Outstanding Shares: 51,100,000
• Free Float: 45,790,000
• Market Cap: $193.67 million
• Optionable: N/A
• Beta: -0.42